Key Takeaways TEM launched xM liquid biopsy to monitor ICI therapy response in solid tumors. Tempus AI introduced Loop, an AI platform combining RWD and CRISPR screens. Development of xH signals TEM's move into WGS to guide hematologic cancer treatment choice.Tempus AI (TEM) continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay to detect molecular response to immune-checkpoin ...

Key Takeaways Myriad Genetics is expanding in oncology diagnostics and prenatal testing for future growth. MYGN's GeneSight test lost UnitedHealthcare coverage, cutting related revenues by 20% year over year. Despite market pressures, MYGN posted four straight earnings beats and maintained strong solvency.Myriad Genetics, Inc. (MYGN) focuses on the expansion of companion diagnostics, market expansion through new clinical guidelines and providing new offerings in its Oncology business. The company plans to ...

Myriad Genetics (MYGN) FY Conference June 11, 2025 02:00 PM ET Speaker0 All right. Good afternoon, everyone. My name is Matt Sykes, the Life Science Tools and Diagnostics Analyst at Goldman Sachs, and I have the pleasure of welcoming Myriad Genetics to our conference this afternoon, Sam Raha, President and CEO and Scott Loeffler, CFO. Sam, Scott, thanks for joining me. Pleasure to be here. Thanks for having us. Speaker1 Thanks for having us, Matt. Speaker0 Great. Maybe, Sam, if we just start off at a high l ...

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaboratorsSALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. Myriad will also highlight how its comprehensive portfolio of ...

Myriad Genetics (MYGN) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Matthew Scalo - SVP, Investor RelationsSam Raha - President & CEOMark Verratti - Chief Operating OfficerScott Leffler - Chief Financial OfficerDoug Schenkel - Managing DirectorPuneet Souda - Senior MDAndrew Cooper - VP - Equity ResearchTycho Peterson - Managing Director, Global EquitiesLu Li - Healthcare Equity Research, DirectorRicki Levitus - Equity Research Associate - Life Sciences Tools & Diagnostics Conference C ...

2024 ANNUAL RESULTS Growth of core business and strategic execution Revenue up 19% to €154 million Organic growth at +9%Proprietary products account for a stable 31% of group revenueInternational accounts for 41% of group revenue Stable 2024 operational results, reflecting pressure on margins and underperformance of some European subsidiariesFree cash flow of €6 millionNet debt of €3.9 million, including EB Development current account Paris, April 28, 2024 - 5:40 pm - Eurobio Scientific (FR0013240934, ALER ...